Results 211 to 220 of about 874,138 (343)

New Insights of Biological Functions of Natural Polyphenols in Inflammatory Intestinal Diseases. [PDF]

Int J Mol Sci, 2023
Zhang Y, Mu T, Deng X, Guo R, Xia B, Jiang L, Wu Z, Liu M.   +7 more
europepmc   +1 more source

Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient‐Reported Measures

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare disorder characterized by fluctuating muscle weakness with potential life‐threatening crises. Timely interventions may be delayed by limited access to care and fragmented documentation. Our objective was to develop predictive algorithms for MG deterioration using multimodal telemedicine data ...
Maike Stein, Haoqi Sun, Sophie Lehnerer, Lea Gerischer, Maximilian Mönch, Christian Meisel, Andreas Meisel, Pushpa Narayanaswami   +7 more
wiley   +1 more source

Evolution of the global burden of vascular intestinal diseases in middle-aged and elderly population: Trend analysis from 1990 to 2021 and projections to 2040. [PDF]

Medicine (Baltimore)
Zhou Z, Zhang T, Shu R, Luo H.
europepmc   +1 more source

Editorial: Engineering probiotics for multiple interventions on intestinal diseases. [PDF]

Front Cell Infect Microbiol, 2023
Huang H, Yin H, Zhang X.
europepmc   +1 more source

Age‐Related Characteristics of SYT1‐Associated Neurodevelopmental Disorder

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives We describe the clinical manifestations and developmental abilities of individuals with SYT1‐associated neurodevelopmental disorder (Baker‐Gordon syndrome) from infancy to adulthood. We further describe the neuroradiological and electrophysiological characteristics of the condition at different ages, and explore the associations ...
Sam G. Norwitz, Josefine Eck, Joel S. Winston, Kate Baker   +3 more
wiley   +1 more source

From Inflammasomes to Pyroptosis: Molecular Mechanisms in Chronic Intestinal Diseases - Opportunity or Challenge? [PDF]

J Inflamm Res
Fang J, Zhu W, Yu D, Zhu L, Zha H, Tang J, Li Y, Zhu X, Zhao T, Zhang W.   +9 more
europepmc   +1 more source

Controversial role of ILC3s in intestinal diseases: A novelty perspective on immunotherapy. [PDF]

Front Immunol, 2023
Zhang Y, Feng X, Chen J, Liu J, Wu J, Tan H, Mi Z, Rong P.   +7 more
europepmc   +1 more source

We are not alone: a case for the human microbiome in extra intestinal diseases [PDF]

, 2017
S. Shivaji
openalex   +1 more source

Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Clinical trials for Huntington's disease (HD) enrolling persons before clinical motor diagnosis (CMD) lack validated biomarkers. This study aimed to conduct an unbiased discovery analysis and a targeted examination of proteomic biomarkers scrutinized by clinical validation. Methods Cerebrospinal fluid was obtained from PREDICT‐HD and
Daniel Chelsky, Cara Joyce, H. Jeremy Bockholt, Paul A. Rudnick, William H. Adams, Fiona McAllister, Justin W. Smock, Michael A. Newton, Jane S. Paulsen   +8 more
wiley   +1 more source

Research Status and Trends of Gut Microbiota and Intestinal Diseases Based on Bibliometrics. [PDF]

Microorganisms
Sun X, Zhai J.
europepmc   +1 more source